Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
This article compares two healthcare ETFs, the VanEck Biotech ETF (BBH) and the State Street SPDR S&P Pharmaceuticals ETF (XPH). It highlights their differing strategies, with BBH focusing on concentrated biotech holdings and XPH offering broader pharmaceutical diversification.
Why it matters
Investors can use this comparison to align their portfolio strategy with either the high-growth potential of biotech or the stability of the broader pharmaceutical sector.
The VanEck Biotech ETF ( BBH +2.75% ) offers concentrated exposure to large-cap biotech leaders, while the State Street SPDR S&P Pharmaceuticals ETF ( XPH +1.60% ) provides broader, more diversified access to the pharmaceutical industry.
Investors seeking targeted healthcare exposure often weigh the specialized growth potential of biotechnology against the broader stability of pharmaceuticals. This comparison examines how these two industry-specific funds differ in strategy, concentration, and long-term results to help determine which approach fits a portfolio's specific needs.
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in